The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

• Status: Completed
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out whether taking eszopiclone (Lunesta) changes the breathing effort required to briefly wake people with obstructive sleep apnea from sleep (respiratory arousal threshold). We would like to see if taking eszopiclone can reduce the severity of obstructive sleep apnea in some people (those that have a low respiratory arousal threshold; i.e. wake up easily to respiratory stimuli).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH); Sunovion
• Treatments: Eszopiclone

Criteria

Inclusion Criteria:

• 18-64 years old

• Untreated obstructive sleep apnea

Exclusion Criteria:

• Nadir SaO2 <70% on a baseline PSG

• Medications known to affect either sleep, breathing or muscle activity

• Major co-morbidities apart from sleep apnea

• Allergy to lidocaine, oxymetazoline HCl, or eszopiclone

• Women who are pregnant